Results 241 to 250 of about 242,891 (382)

Population Pharmacokinetics of Dupilumab in Adults, Adolescents, and Children With Eosinophilic Esophagitis

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Dupilumab, a fully human monoclonal antibody that blocks key drivers of type 2 inflammation, is approved across 8 diseases, including eosinophilic esophagitis. Subcutaneous dupilumab 300 mg weekly improved outcomes vs. placebo in adults (aged ≥ 18 years) and adolescents (aged ≥ 12 to < 18 years) during the phase III LIBERTY EoE TREET study (NCT03633617)
Jenny‐Hoa Nguyen   +8 more
wiley   +1 more source

Families being supportive together: A multimethod and multi-informant intensive longitudinal study of family protective mechanisms for adolescent depression. [PDF]

open access: yesPsychol Assess
Bai S   +12 more
europepmc   +1 more source

Accelerating Generic Long‐Acting Antiretrovirals for Global HIV Treatment: Workshop Findings and a Roadmap to Access

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The global HIV response aims for widespread availability of affordable, quality‐assured long‐acting antiretroviral (LA ARV) drugs to achieve sustained epidemic control, particularly in low‐ and middle‐income countries. This report summarizes key discussion points, findings, and outcomes from an international workshop on generic LA ARVs, held in ...
Usman Arshad   +22 more
wiley   +1 more source

Implementation of OMOP and ConcePTION Common Data Models in CPRD GOLD: Risk of Bleeding and Cardiovascular Outcomes From Anticoagulant Use

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The impact of the choice of common data model (CDM) approach on the study results in a real‐world evidence (RWE) study is unknown. We aimed to determine potential differences in the results of an RWE study when data were mapped to two different CDMs, ConcePTION and OMOP. With the same instance of CPRD GOLD, data were mapped to both CDMs. Using the same
Nicholas B. Hunt   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy